Literature DB >> 21248757

Hypertension augments cardiac Toll-like receptor 4 expression and activity.

Ruth Eissler1, Christoph Schmaderer, Krisztina Rusai, Louisa Kühne, Daniel Sollinger, Tobias Lahmer, Oliver Witzke, Jens Lutz, Uwe Heemann, Marcus Baumann.   

Abstract

Hypertension causes cardiac hypertrophy characterized by low-grade inflammation. Toll-like receptors (TLRs), members of the innate immune system, contribute to cardiac failure. We hypothesized that hypertension is accompanied by enhanced TLR4 expression and activity. Cardiac TLR4 expression was determined in untreated spontaneously hypertensive rats (SHR) and normotensive Wistar-Kyoto rats (WKY; 4, 8, 16 weeks). Besides, hearts of 8-week-old rats were stimulated with the endogenous TLR4 ligand heparansulfate (HS); the proinflammatory mRNA pattern was assessed (tumor necrosis factor-α (TNF-α), interleukin (IL)-6, monocyte chemotactic protein (MCP)-1). Additionally, we induced hypertension in WKY by L-NAME (N(ω)-nitro-L-arginine-methylester hydrochloride). In both hypertension models the effect of ramipril on TLR4 density was assessed. Cardiac TLR4 distribution was investigated by fluorescence-activated cell sorting analysis. Blood pressure (BP) and heart weight/body weight ratio (HW/BW) were elevated in SHR. Constitutive TLR4 expression was augmented in adolescent and adult, but not young SHR compared with WKY. TLR4 staining was pronounced in cardiomyocytes. HS entailed an aggravated TNF-α and IL-6 mRNA response in cardiac tissue, which was significantly pronounced in SHR. Ramipril (10 mg kg(-1) per day) reduced BP, HW/BW and TLR4 expression in SHR. L-NAME also augmented TLR4 expression in WKY. Ramipril (1 mg kg(-1) per day) lowered BP but TLR4 expression remained unaffected. High-dose ramipril (10 mg kg(-1) per day) however decreased TLR4 expression. Starting from adolescence SHR demonstrated enhanced cardiac TLR4 expression. TLR4 was also upregulated in L-NAME induced hypertension. Thus, enhanced TLR4 expression might be linked to the development and maintenance of hypertension. Finally, the antihypertensive, anti-inflammatory action of angiotensin-converting-enzyme inhibition had no effect on TLR4 expression in therapeutic doses but in a high-dose model.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21248757     DOI: 10.1038/hr.2010.270

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  47 in total

Review 1.  Immune Mechanisms in Arterial Hypertension.

Authors:  Ulrich Wenzel; Jan Eric Turner; Christian Krebs; Christian Kurts; David G Harrison; Heimo Ehmke
Journal:  J Am Soc Nephrol       Date:  2015-08-28       Impact factor: 10.121

Review 2.  Immunity in arterial hypertension: associations or causalities?

Authors:  Hans-Joachim Anders; Marcus Baumann; Giovanni Tripepi; Francesca Mallamaci
Journal:  Nephrol Dial Transplant       Date:  2015-03-11       Impact factor: 5.992

Review 3.  Antihypertensive Effects of Probiotics.

Authors:  Iñaki Robles-Vera; Marta Toral; Miguel Romero; Rosario Jiménez; Manuel Sánchez; Francisco Pérez-Vizcaíno; Juan Duarte
Journal:  Curr Hypertens Rep       Date:  2017-04       Impact factor: 5.369

4.  Genetic disruption of Npr1 depletes regulatory T cells and provokes high levels of proinflammatory cytokines and fibrosis in the kidneys of female mutant mice.

Authors:  Venkateswara Reddy Gogulamudi; Indra Mani; Umadevi Subramanian; Kailash N Pandey
Journal:  Am J Physiol Renal Physiol       Date:  2019-04-03

Review 5.  The immune system and hypertension.

Authors:  Madhu V Singh; Mark W Chapleau; Sailesh C Harwani; Francois M Abboud
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

6.  Are the leukocyte telomere length attrition and telomerase activity alteration potential predictor biomarkers for sporadic TAA in aged individuals?

Authors:  Carmela R Balistreri; Calogera Pisano; Adriana Martorana; Oreste F Triolo; Domenico Lio; Giuseppina Candore; Giovanni Ruvolo
Journal:  Age (Dordr)       Date:  2014-08-17

7.  Toll-like receptor 4 mutation suppresses hyperhomocysteinemia-induced hypertension.

Authors:  Anastasia Familtseva; Pankaj Chaturvedi; Anuradha Kalani; Nevena Jeremic; Naira Metreveli; George H Kunkel; Suresh C Tyagi
Journal:  Am J Physiol Cell Physiol       Date:  2016-08-03       Impact factor: 4.249

8.  Angiotensin Ⅱ Activates MCP-1 and Induces Cardiac Hypertrophy and Dysfunction via Toll-like Receptor 4.

Authors:  Susumu Matsuda; Seiji Umemoto; Koichi Yoshimura; Shinichi Itoh; Tomoaki Murata; Tohru Fukai; Masunori Matsuzaki
Journal:  J Atheroscler Thromb       Date:  2015-03-05       Impact factor: 4.928

Review 9.  Novel Targets for Hypertension Drug Discovery.

Authors:  Lokesh Kumar Bhatt; Ishant Selokar; Dezaree Raut; Tahir Hussain
Journal:  Curr Hypertens Rep       Date:  2021-03-30       Impact factor: 5.369

10.  Double-stranded RNA-dependent protein kinase deficiency protects the heart from systolic overload-induced congestive heart failure.

Authors:  Huan Wang; Xin Xu; John Fassett; Dongmin Kwak; Xiaoyu Liu; Xinli Hu; Therasa J Falls; John C Bell; Hongliang Li; Peter Bitterman; Robert J Bache; Yingjie Chen
Journal:  Circulation       Date:  2014-01-24       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.